<?xml version="1.0" encoding="UTF-8"?>
<p>Correspondingly, in clinical trial, severe dengue (DHS/DSS), virologically confirmed dengue, and hospitalization were the three major parameters to evaluate DENV vaccine candidates (
 <xref rid="B73" ref-type="bibr">Hadinegoro et al., 2015</xref>; 
 <xref rid="B14" ref-type="bibr">Biswal et al., 2019</xref>). In addition to these three parameters, for the evaluation of ZIKV vaccine, other parameters might have to be included, such as neurological diseases (Guillain-Barre syndrome, fetal brain development abnormality).
</p>
